Cellular Basis for the Antifungal Activity of Amiodarone

这项提议的目的是阐明一种新的抗真菌药物导致的细胞程序性死亡的途径。 并探索其作为抗真菌辅助剂的用途。胺碘酮是一种有效的抗心律失常药物 最近发现具有有效和广泛的杀菌活性。我们已经证明了胺碘酮 酿酒酵母的毒性是通过破坏钙稳态介导的，其次是 通过细胞凋亡标记物和细胞死亡的出现。在目标1中，我们建议结合使用 生物化学和细胞生物学方法来确定事件的身份和时间顺序 从最初的胞浆钙爆发到细胞死亡。我们将寻求验证致病因素中的关键发现 白色念珠菌作为胺碘酮广泛性杀菌机理的原则性证明。 在目标2中，我们将使用各种全基因组方法来识别 导致胺碘酮诱导的细胞死亡。这些研究确定的基因将被组织成 生物模块，并通过集成来自高通量的实验数据放置在细胞路径中 利用在线数据库中的信息进行生化分析，以提供药物毒性的全球视角。我们有 结果表明，低剂量的胺碘酮与现有的抗真菌药物有很强的协同作用。 念珠菌、隐球菌属和曲霉属真菌种类。来自这些体外研究的药物协同作用将形成 将在系统性念珠菌病小鼠模型中探索的联合治疗的基础(Aim3)。 综上所述，这些研究将开发钙介导的细胞死亡途径作为一种主要的新药 发现目标机会。胺碘酮将作为靶向这一途径的模型试验化合物 用于验证一类新型抗真菌增强剂的潜力。 该项目的公共卫生相关性源于新的真菌病原体和药物的出现 在管理真菌感染方面，迫切需要有替代战略。

The goal of this proposal is to elucidate the pathway of programmed cell death by a novel antifungal agent and explore its use as an antimycotic adjunct. Amiodarone is an effective antiarrhythmic drug that was recently discovered to have potent and broad range fungicidal activity. We have shown that amiodarone toxicity in the yeast Saccharomyces cerevisiae is mediated by disruption of calcium homeostasis, followed by the appearance of apoptosis markers and cell death. In Aim 1, we propose to use a combination of biochemical and cell biological approaches to determine the identity and temporal order of events leading from the initial burst of cytosolic calcium to cell death. We will seek to validate key findings in the pathogenic yeast Candida albicans as proof-of-principle for the universality of the fungicidal mechanism of amiodarone. In Aim 2, we will use a variety of genome-wide approaches to identify the genes and signaling pathways that contribute to amiodarone-induced cell death. Genes identified by these studies will be organized into biomodules and placed in cellular pathways by integrating experimental data from high-throughput biochemical assays with information from online databases to give a global view of drug toxicity. We have shown that low doses of amiodarone exhibit potent synergism with existing antifungals against pathogenic fungal species of Candida, Cryptococcus and Aspergillus. Drug synergy from these in vitro studies will form the basis for combination therapy that will be explored in a murine model of systemic Candidiasis (Aim3). Taken together these studies will develop the calcium-mediated cell death pathway as a major new drug discovery target opportunity. Amiodarone will serve as a model test compound for targeting this pathway and for validating the potential of a new class of antifungal potentiating agents. The public health relevance of this project arises from the emergence of new fungal pathogens and drug resistant fungi, and the urgent need for alternative strategies in the management of fungal infections.